Details of the Drug Combinations

General Information of This Drug (ID: DMLZ89P)

Drug Name
KN-62   DMLZ89P
Synonyms KN-62 (non-isomeric); GTPL6001; HMS3229A04; CCG-206863
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

35 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Artemether + KN-62 DCH046X Artemether DD2 (Cell Line: DD2) [2]
Chloroquine + KN-62 DCR4AZV Chloroquine DD2 (Cell Line: DD2) [2]
Diltiazem + KN-62 DCOVDVO Diltiazem DD2 (Cell Line: DD2) [2]
Diltiazem + KN-62 DC383OH Diltiazem Hepatoblastoma (Cell Line: HB3) [3]
KN-62 + OZ277 DC4OOIE OZ277 DD2 (Cell Line: DD2) [2]
KN-62 + Lumefantrine DCRM15J Lumefantrine DD2 (Cell Line: DD2) [2]
KN-62 + Carfilzomib DCB84PH Carfilzomib DD2 (Cell Line: DD2) [2]
KN-62 + Alvespimycin hydrochloride DCL70L8 Alvespimycin hydrochloride DD2 (Cell Line: DD2) [2]
KN-62 + Diltiazem DCVX98A Diltiazem DD2 (Cell Line: DD2) [2]
KN-62 + Tranylcypromine DCD4SM1 Tranylcypromine DD2 (Cell Line: DD2) [2]
KN-62 + GSK2126458 DCZDILF GSK2126458 DD2 (Cell Line: DD2) [2]
KN-62 + Methylene blue DCJR6WL Methylene blue DD2 (Cell Line: DD2) [2]
KN-62 + Bardoxolone methyl DCWZKBH Bardoxolone methyl DD2 (Cell Line: DD2) [2]
KN-62 + Artemisinin DCPGVGW Artemisinin DD2 (Cell Line: DD2) [2]
KN-62 + Naltrexone DCM1R1U Naltrexone DD2 (Cell Line: DD2) [2]
KN-62 + Piperaquine DCM84DP Piperaquine DD2 (Cell Line: DD2) [2]
KN-62 + Mefloquine DCGXNN9 Mefloquine DD2 (Cell Line: DD2) [2]
KN-62 + CPG 52364 DCIMPNE CPG 52364 DD2 (Cell Line: DD2) [2]
KN-62 + Primaquine DC2RXM4 Primaquine DD2 (Cell Line: DD2) [2]
KN-62 + Atovaquone DC25VEX Atovaquone DD2 (Cell Line: DD2) [2]
KN-62 + OZ277 DC15OO8 OZ277 Hepatoblastoma (Cell Line: HB3) [3]
KN-62 + Lumefantrine DCX2TA2 Lumefantrine Hepatoblastoma (Cell Line: HB3) [3]
KN-62 + Artemether DCOHYY3 Artemether Hepatoblastoma (Cell Line: HB3) [3]
KN-62 + Diltiazem DCVJT4P Diltiazem Hepatoblastoma (Cell Line: HB3) [3]
KN-62 + GSK2126458 DCMT928 GSK2126458 Hepatoblastoma (Cell Line: HB3) [3]
KN-62 + Methylene blue DC6N1D6 Methylene blue Hepatoblastoma (Cell Line: HB3) [3]
KN-62 + Artemisinin DCO8R50 Artemisinin Hepatoblastoma (Cell Line: HB3) [3]
KN-62 + Naltrexone DC7MDE5 Naltrexone Hepatoblastoma (Cell Line: HB3) [3]
KN-62 + Quinine DCKENE5 Quinine Hepatoblastoma (Cell Line: HB3) [3]
KN-62 + Piperaquine DCEYGGX Piperaquine Hepatoblastoma (Cell Line: HB3) [3]
KN-62 + Mefloquine DC5H4D3 Mefloquine Hepatoblastoma (Cell Line: HB3) [3]
KN-62 + Atovaquone DCLFLLY Atovaquone Hepatoblastoma (Cell Line: HB3) [3]
Lumefantrine + KN-62 DCYGMT0 Lumefantrine DD2 (Cell Line: DD2) [2]
Mefloquine + KN-62 DC4OXL1 Mefloquine Hepatoblastoma (Cell Line: HB3) [2]
TG100-115 + KN-62 DCER5QQ TG100-115 Hepatoblastoma (Cell Line: HB3) [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 35 DrugCom(s)

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6001).
2 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.